Mode
Text Size
Log in / Sign up
N/A N=142 Randomized Single-blind Treatment

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

Schizophrenia · Schizoaffective Disorder

Enrolled (actual)
142
Serious AEs
0.0%
Results posted
Oct 2015
Primary outcome: Primary: Adherence — 91.84; 88.61; 72.55 Percentage of medication taken

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Med-eMonitor (Behavioral); PharmCAT (Behavioral); Treatment as Usual (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center at San Antonio
Primary completion
Jul 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Adherence
91.84; 88.61; 72.55
PRIMARY
Social and Occupational Functioning Assessment Scale (SOFAS) Scores
91.84; 88.61; 73.19
SECONDARY
Schizophrenia Symptoms
2.73; 2.75; 2.72

Summary

This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV criteria, as determined on the basis of the Structured Clinical Interview for Diagnosis (SCID-P)
  • Receiving treatment with an oral atypical antipsychotic medication other than clozapine (e.g., risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, or others as they are FDA approved)
  • Assumes some responsibility for taking own medications
  • Able to provide evidence of a stable living environment (e.g., individual apartment, family home, or board and care facility) within 3 months prior to study entry and no plans to move in the next year
  • Intact visual and auditory ability as determined by a computerized screening battery
  • Ability to read at the 5th grade level or higher based upon score on the Wide Range Achievement Test (WRAT)
  • Able to understand and complete rating scales and neuropsychological testing
  • Working telephone present in the home

Exclusion Criteria

  • History of significant head trauma, seizure disorder, or mental retardation
  • Alcohol or drug abuse or dependence within 3 months prior to study entry
  • Currently being treated by an assertive community treatment (ACT) team
  • History of violence within 1 year prior to study entry
  • Any hospitalizations within 3 months prior to study entry
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00406718). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search